Differential Impact of Adherence to Pegylated Interferon and Ribavirin in the Treatment of Genotype 1 High Viral Titer Chronic Hepatitis C

Table 1

Variables	SVR	P-value	Adjusted OR (95% C.I.)	P-value
Sex		.091		.501
Female	20/45 (44.4%)		1.00
Male	47/77 (61.0%)		1.429 (0.506–4.032)
Age (yr)		.019		.398
65<	5/16 (31.3%)		1.00
51< ≤64	35/68 (51.5%)		2.655 (0.581–12.132)
≤50	27/38 (71.1%)		2.695 (0.574–12.659)
Weight (Kg)		.028		.116
<65	31/68 (45.6%)		1.000
65≤	36/54 (66.7%)		3.053 (0.760–12.274)
BMI		.716		.158
24≤	30/57 (52.6%)		1.000
<24	37/65 (56.9%)		2.747 (0.674–11.236)
Viral load (IU/mL)		.015		.174
800,000≤	41/86 (47.7%)		1.000
100,000≤ <800,000	26/36 (72.2%)		2.137 (0.716–6.369)
History of IFN treatment		.203		.581
yes	26/54 (48.1%)		1.000
no	41/68 (60.3%)		1.316 (0.496–3.493)
Peg-IFN adherence (%)		<.001		.008
<60	6/22 (27.3%)		2.637 (0.448–15.513)	.284
60≤ <80	4/21 (19.0%)		1.000	—
80≤	57/79 (72.2%)		7.702 (1.926–30.798)	.004
RBV adherence (%)		<.001		.010
<60	1/19 (5.3%)		1.000	—
60≤ <80	7/17 (41.2%)		15.679 (1.289–190.653)	.031
80≤	59/86 (68.6%)		27.416 (3.130–240.151)	.003